Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quinoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL28090169 | 0.98 | ALDH1A1 (0.65) | ALDH1A1POLBPDE10AMEN1KMT2A | |
| Quinoline SCHEMBL11837716 | 0.88 | ALDH1A1 (0.53) | ALDH1A1POLBPDE10AMEN1KMT2A | |
| Quinoline SCHEMBL11837706 | 0.88 | ALDH1A1 (0.53) | ALDH1A1POLBPDE10AMEN1KMT2A | |
| Quinoline SCHEMBL27700047 | 0.85 | ALDH1A1 (0.85) | ALDH1A1POLBMEN1KMT2ACASP1 | |
| Quinoline SCHEMBL27814435 | 0.85 | POLB (0.64) | ALDH1A1POLBPDE10AMEN1KMT2A | |
| Quinoline SCHEMBL7208557 | 0.83 | ALDH1A1 (0.90) | ALDH1A1POLBMEN1KMT2ACASP1 | |
| Quinoline SCHEMBL32661377 | 0.82 | ALDH1A1 (1.00) | ALDH1A1POLBPDE10AMEN1KMT2A | |
| Quinoline SCHEMBL29349552 | 0.82 | ALDH1A1 (1.00) | ALDH1A1POLBPDE10AMEN1KMT2A | |
| Quinoline SCHEMBL29822171 | 0.82 | ALDH1A1 (1.00) | ALDH1A1POLBPDE10AMEN1KMT2A | |
| Quinoline SCHEMBL2774 | 0.82 | ALDH1A1 (1.00) | ALDH1A1POLBPDE10AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-53044576-A | — | — | None | — | — | JP | disclosed |
| CN-113046737-A | Method for treating metal surface by using hydroxylamine zinc phosphating solution | 廊坊师范学院 | 2021-06-29 | — | — | CN | disclosed |
| CN-106399146-B | Bacillus subtilis ZKGS01 and its application in prevention and treatment fungal diseases of plants | 北京中科金株生物科技有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-105572127-A | Preparation method of quimociac reagent | TIANJIN GUANGFU TECH DEV CO LTD | 2016-05-11 | — | — | CN | disclosed |
| US-7128976-B2 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| CN-1193792-C | Stable medicinal composition for oral use | YAMANOUCHI PHARMA CO LTD (JP) | 2005-03-23 | — | — | CN | disclosed |
| CN-1142145-C | Process for preparation of 2,3-pyridine dicarboxylic acid | DSM��ϸ��ѧ�µ�������˾ | 2004-03-17 | — | — | CN | disclosed |
| US-20030091838-A1 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2003-05-15 | — | — | US | disclosed |
| CN-1373673-A | Stable medicinal composition for oral use | YAMANOUCHI PHARMA CO LTD (JP) | 2002-10-09 | — | — | CN | disclosed |
| US-6395903-B1 | REACTING A QUINOLINE IN AQUEOUS SULFURIC ACID OR NITRIC ACID SOLUTION WITH OZONE, AND THEN REACTING THE RESULTING PEROXIDE SOLUTION WITH AN OXIDIZING AGENT; ADJUSTING THE PH TO 0.2 TO 3; COOLING TO 0-30 DEGREES C.; ISOLATION | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2002-05-28 | — | — | US | disclosed |
| US-20020062025-A1 | PROCESS FOR THE PREPARATION OF 2,3-PYRIDINEICARBOXYLIC ACIDS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2002-05-23 | — | — | US | disclosed |
| CN-1274720-A | Process for preparation of 2,3-pyridine dicarboxylic acid | DSM FINE CHEMICAL AUSTRIA GMBH (AT) | 2000-11-29 | — | — | CN | disclosed |
| JP-S5344576-A | NITRATION OF QUINOLEINES | TEIJIN LTD | 1978-04-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062025-A1 | PROCESS FOR THE PREPARATION OF 2,3-PYRIDINEICARBOXYLIC ACIDS | CBR1, HAO2, SCO2 | ALDH1A1 482/4885POLB 826/4885PDE10A 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.